Anti-PD1 antibody [EPR4877(2)] is a rabbit recombinant monoclonal antibody that is used to detect PD1 in IHC-P. Suitable for Human samples.
- Using biophysical QC, antibody identity is confirmed at a molecular level for unrivaled batch-batch consistency
- Specificity and sensitivity confirmed in IHC with multi-tissue microarray (TMA) validation
- Antibody clone EPR4877(2) is cited in over 120 publications
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IHC-P | Flow Cyt | ICC/IF | |
---|---|---|---|
Human | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/250 - 1/500 | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
The protein expressed by the gene PDCD1 functions as an inhibitory receptor on antigen-activated T-cells, playing a critical role in the induction and maintenance of immune tolerance to self. It delivers inhibitory signals by binding to the ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Tumors exploit the PDCD1-mediated inhibitory pathway to attenuate anti-tumor immunity, enabling tumor survival by evading immune system destruction. The interaction with CD274/PDCD1L1 inhibits the effector function of cytotoxic T lymphocytes (CTLs). Blocking the PDCD1-mediated pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, providing a rationale for cancer immunotherapy. This supplementary information is collated from multiple sources and compiled automatically.
CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1
Anti-PD1 antibody [EPR4877(2)] is a rabbit recombinant monoclonal antibody that is used to detect PD1 in IHC-P. Suitable for Human samples.
- Using biophysical QC, antibody identity is confirmed at a molecular level for unrivaled batch-batch consistency
- Specificity and sensitivity confirmed in IHC with multi-tissue microarray (TMA) validation
- Antibody clone EPR4877(2) is cited in over 120 publications
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Anti-PD1 antibody [EPR4877(2)] (ab137132) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P .
Anti-PD1 antibody [EPR4877(2)] (ab137132) was first used in a scientific publication in 2014 and has been cited over 101 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [EPR4877(2)] (ab137132) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-PD1 antibody [EPR4877(2)] (ab137132) has 5 independent reviews from customers.
Anti-PD1 antibody [EPR4877(2)] (ab137132) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL).
Conjugation-ready, carrier free format available for antibody clone EPR4877(2) - Anti-PD1 antibody [EPR4877(2)] - BSA and Azide free ab186928.
Antibody clone EPR4877(2) is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 555, Alexa Fluor® 594, Alexa Fluor® 488, Alexa Fluor® 568, Alexa Fluor® 750 (Alexa Fluor® 647 Anti-PD1 antibody [EPR4877(2)] ab201825, Alexa Fluor® 555 Anti-PD1 antibody [EPR4877(2)] ab275126, Alexa Fluor® 594 Anti-PD1 antibody [EPR4877(2)] ab275349, Alexa Fluor® 488 Anti-PD1 antibody [EPR4877(2)] ab311022, Alexa Fluor® 568 Anti-PD1 antibody [EPR4877(2)] ab313074, Alexa Fluor® 750 Anti-PD1 antibody [EPR4877(2)] ab321110).
PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1’s expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.
PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.
PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1’s regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of formaldehyde fixed human tonsil staining with ab137132 at 1/500 dilution. Secondary antibody used was BOND Refine Detection. The sample was incubated with the primary antibody for 30 minutes. Antigen retrieval method was heat mediated BOND ER2
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labeling PD1 with purified ab137132 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. Goat Anti-Rabbit IgG H&L (HRP) ab97051, an HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500).
Negative control: Secondary antibody only using PBS instead of primary antibody. Counterstained with hematoxylin.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labeling PD1 with ab137132 at a dilution of 1/500. Heat mediated antigen retrieval was performed using EDTA antigen retrieval solution, and microwave treatment for 20 min at 20% power. Anti-Rabbit HRP polymer was used as secondary antibody. Opal tyramide amplification was performed using Opal 540 fluorophore. Counterstained with DAPI stain.
Image scanned with Vectra 3.0 and analyzed via Inform software.
This image was courteously provided by Dr. Houssein Abdul Sater, Georgia Cancer Center.
Formalin-fixed paraffin-embedded early RA synovial biopsies were cut into 5 μM sections and mounted on Fisherbrand Superfrost Plus Slides. The sections were stained with anti-CD3 and anti-PD1 (ab137132, Abcam) antibodies. The markers were visualized with 3,3'-diaminobenzidine and the relative expression of each marker was noted. CD3 and PD1 staining was reported as CD3+% or PD1+% cells within a total magnification of 100x across the entire biopsy section.
Immunohistochemical analysis using ab137132 (unpurified version) showing negative staining in normal human brain tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemical analysis using ab137132 (unpurified) showing negative staining in human skeletal muscle tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human T-cell lymphoma tissue labeling PD1 with unpurified ab137132 at a dilution of 1/250.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labeling PD1 with unpurified ab137132 at a dilution of 1/250.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Tissue Microarrays stained for "Anti-PD1 antibody [EPR4877(2)]" using "ab137132"in immunohistochemical analysis. This table provides a detailed overview of positive (tick mark) and negative (cross mark) staining per sample type tested. The sections were pre-treated using Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0) for 20 minutes. The sections were incubated with ab137132 for 30 mins at room temperature followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101). The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com